Assembly Biosciences (ASMB) AI Stock Analysis

• Market Cap: $453.36M
• Dividend Yield: N/A
• Average Volume (3M): 164.41K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.31
• Revenue Growth: 31.30%
• EPS Growth: 32.79%
• Country: US
• Employees: 73
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 2.67
• Shares Outstanding: 15,862,705
• 10 Day Avg. Volume: 178,321
• 30 Day Avg. Volume: 164,409
• PEG Ratio: 0.68
• Price to Book (P/B): 1.84
• Price to Sales (P/S): 5.27
• P/FCF Ratio: -9.26
• Enterprise Value/Market Cap: 0.87
• Enterprise Value/Revenue: 5.48
• Enterprise Value/Gross Profit: 7.06
• Enterprise Value/Ebitda: -38.46
• 1Y Price Target: $50.00
• Price Target Upside: 74.95% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -4.04
• Revenue Forecast (FY): $21.80M

• Rating: 45 Neutral
• Price Target: $27.00 ▼(-5.53% Downside)
• Action: Reiterated Date: 03/20/26
• Date: Action: Reiterated 03/20/26

The score is primarily held back by weak financial performance—recurring losses, zero revenue in 2025, and ongoing cash burn—despite low leverage. Technicals are mixed but skew weak with negative momentum indicators and price below key short-to-mid-term averages. Valuation adds further caution due to negative earnings and no dividend support.

Positive Factors

Focused clinical-stage pipeline (HBV specialization)

A concentrated R&D focus on antiviral therapeutics, notably chronic HBV, creates durable scientific and market specialization. This allows targeted resource allocation, deeper domain expertise, and clearer partnering/licensing prospects that support long-term development and commercialization pathways.

Low financial leverage

Low debt levels reduce solvency risk and preserve financial optionality over months. For a cash-burning biotech, modest leverage lessens bankruptcy risk and makes future financings or partnerships easier to execute without immediate debt-service pressures.

Established access to capital (shelf filing)

A $400M mixed securities shelf is a structural funding tool that expands the company's ability to raise equity/debt efficiently. That durable financing flexibility supports ongoing trials and operations, reducing short-term cash risk and enabling strategic capital deployment.

Negative Factors

Persistent negative operating and free cash flow

Consistent operating and free cash flow deficits indicate the company cannot self-fund development reliably. Over 2-6 months this necessitates external financing or spend cuts, constraining R&D pacing and increasing dilution or financing cost risks for long-term program support.

Volatile and interrupted revenue generation

Revenue volatility and a drop to zero in 2025 undermine predictability for sustaining operations and indicate reliance on irregular, non-recurring revenue streams. This structural inconsistency weakens the firm's ability to plan long-term commercial expansion or reinvestment.

Persistent losses and dilution/financing dependency

Ongoing unprofitability creates a structural reliance on capital markets or partners. Historical swings in equity imply prior raises; continued losses increase probability of future dilution, which can pressure shareholder value and limit strategic flexibility over the medium term.

Assembly Biosciences Business Overview & Revenue Model

Company Description

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

How the Company Makes Money

null

Assembly Biosciences Financial Statement Overview

Summary

Financial profile is constrained by persistent losses, highly uneven revenue (including zero revenue in 2025), and sustained negative operating/free cash flow indicating ongoing funding needs. The main offset is relatively low leverage, which reduces balance-sheet risk versus many peers.

Income Statement

Profitability remains weak and volatile. The company generated revenue in some years (notably 2020 and 2024), but revenue dropped to zero in 2025, implying a sharp disruption in the top line. Losses are persistent across the period, with negative operating results each year and historically very large loss levels; while the 2025 loss narrowed versus prior years, the underlying earnings profile is still firmly unprofitable and highly dependent on non-recurring or uncertain revenue sources.

Balance Sheet

Leverage is low, which reduces financial risk: debt is small relative to equity across all years (debt-to-equity generally in the low single digits to low double digits). However, shareholder returns are consistently negative, reflecting ongoing losses, and equity levels have swung meaningfully year to year (e.g., much higher in 2025 than 2024), which can signal capital raises and dilution risk typical for biotech companies.

Cash Flow

Cash generation is a key pressure point. Operating and free cash flow are negative in most years, including a sizable cash burn in 2024 and 2025, and free cash flow declined further in 2025 versus 2024. There was a one-year improvement in 2023 with positive operating and free cash flow, but the reversal back to heavy burn suggests limited consistency in funding operations internally and a continued need for external financing.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	72.30M	28.52M	7.16M	0.00	6.25M
Gross Profit	72.17M	28.52M	-41.74M	-69.08M	6.25M
EBITDA	-11.99M	-45.29M	-64.20M	-92.52M	-90.58M
Net Income	-6.12M	-40.18M	-61.23M	-93.09M	-129.85M
Balance Sheet
Total Assets	257.59M	119.17M	136.82M	101.79M	191.06M
Cash, Cash Equivalents and Short-Term Investments	248.11M	112.08M	130.25M	91.61M	146.63M
Total Debt	2.63M	3.09M	2.34M	3.46M	6.48M
Total Liabilities	50.84M	85.81M	95.73M	19.13M	22.13M
Stockholders Equity	206.75M	33.36M	41.10M	82.66M	168.93M
Cash Flow
Free Cash Flow	-41.16M	-51.15M	22.49M	-84.56M	-96.49M
Operating Cash Flow	-41.09M	-51.12M	22.74M	-84.46M	-93.40M
Investing Cash Flow	-113.47M	40.17M	-69.14M	90.64M	26.52M
Financing Cash Flow	174.67M	29.45M	13.82M	614.00K	53.06M

Assembly Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 28.58
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASMB, the sentiment is Positive. The current price of 28.58 is below the 20-day moving average (MA) of 28.82, above the 50-day MA of 28.25, and above the 200-day MA of 26.64, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 50.31 is Neutral, neither overbought nor oversold. The STOCH value of 35.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ASMB.

Assembly Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANNX	56 Neutral	$777.19M	-2.07	-92.28%	―	―	-35.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VOR	50 Neutral	$526.89M	-0.10	274.58%	―	―	-1072.48%
BNTC	49 Neutral	$384.42M	-13.08	-38.92%	―	―	80.95%
QSI	46 Neutral	$194.30M	-2.15	-43.90%	―	40.20%	-4.07%
LXEO	46 Neutral	$404.35M	-4.99	-90.49%	―	―	4.97%
ASMB	45 Neutral	$453.36M	-62.28	-59.01%	―	31.30%	32.79%